Fitness, Health and Nutrition
November 17, 2026
CATEGORY: DIET & WEIGHT
The weight-loss drug tirzepatide has now finished its first full trial in teenagers, and the results look a lot like the adult ones. Over 72 weeks, BMI fell 18.5% in adolescents with obesity who took the weekly shot, while it rose 0.5% in those on placebo.1 Body weight dropped 16.9% against a 2.2% gain. By the end, 53.5% of the treated teens no longer measured in the obese range at all. On placebo, 7.1% did.
The trial, named SURMOUNT-ADOLESCENTS, enrolled 160 adolescents ages 12 to 17 at 31 centers in Canada, the Czech Republic, Israel, Italy, Poland and the United States. Nearly all had obesity, most of it severe, with a starting BMI around 38. BMI, or body mass index, is weight measured against height, and in growing teens it’s the standard yardstick for obesity. Every participant got counseling on healthy food and activity. On top of that, a computer decided who received weekly tirzepatide injections and who received identical dummy shots, two teens on the drug for every one on placebo. Families and study doctors were kept in the dark about who had which. The doses rose stepwise to the highest amount each teen could comfortably tolerate.
Nearly half of the treated teens, 48.1%, saw their BMI fall by a fifth or more. Among placebo teens, 7.9% did. Waistlines shrank by about 16 centimeters more than placebo, roughly six inches. Systolic blood pressure came down 5.6 mmHg more, LDL cholesterol and triglycerides fell further, and total body fat measured by X-ray scanning dropped by about a third more than in the placebo group. The treated teens also reported feeling more physically comfortable in their bodies on a quality-of-life questionnaire built for young people. Every one of the trial’s ten key secondary measures favored the drug.
Side effects clustered in the gut, mostly while doses were being raised. About half of the treated teens vomited at least once, half had nausea, and 45% had diarrhea. Ten of them, about 1 in 11, stopped the drug over side effects. Nobody on placebo stopped for that reason. Serious adverse events touched 7.4% of the tirzepatide group and 3.9% of the placebo group. Five treated teens and one placebo teen reported depression or suicidal thoughts; none of these was judged serious, and all had a prior psychiatric history. The question that hangs over any obesity drug in a 14-year-old is growth, and here the news is reassuring so far. Height tracked as expected in both groups, puberty progressed normally, and the researchers saw no signal of disrupted growth or maturation. Most participants were already late in puberty, though, so the trial says little about younger or less developed children. Eli Lilly, the drug’s maker, funded the study.
Tirzepatide is approved for adults with obesity, but not for anyone under 18; in children it’s approved only for type 2 diabetes from age 10. There’s a clear precedent for what happens next. Semaglutide went through a similar adolescent trial in 2022, cutting BMI 16.1% while placebo rose 0.6%, and won approval for ages 12 and up soon after.2 This trial makes tirzepatide the second drug of its generation to post that kind of result in teens rather than the first.
For educational purposes only — not medical advice. Consult your clinician before acting on this content.
From Fitness, Health and Nutrition: https://fitnesshealthandnutrition.com/2026/11/17/tirzepatide-teens-obesity-trial/